Vistagen Therapeutics, Inc. VTGN 深 沪
等待开盘 09-09 09:30:00 美东时间
0.2434
+0.001
+0.25%
华盛通- 最 高0.25
- 今 开0.25
- 成交量 31.93万股
- 最 低 0.24
- 昨 收 0.2428
- 总市值 1080.13万
- 52周最高 5.14
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 0.198
- 委 比 89.69%
- 总股本 4437.69万
- 历史最高 495.00
- 量 比 0.86
- 振 幅 4.12%
- 历史最低 0.198
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $1.476 m...
08-14 20:50
VistaGen reports Phase 2 fasedienol trial topline results
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On August 6, 2026...
08-07 05:36
Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold...
07-06 13:55
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population. However, the company identified a statistically significant benefit in a pos...
07-01 01:35
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $465.0...
06-16 05:18
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
VistaGen Therapeutics ( ($VTGN) ) just unveiled an update. On May 8, 2026, Vist...
05-09 06:07
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
05-08 19:42
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On April 22, 2026...
04-29 04:31
Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
04-22 20:35
